[Clinical trial of delayed-action Akinophyl (Akineton)].
D000433:1-Propanol; D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001008:Anxiety Disorders / Q000188:drug therapy; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D001712:Biperiden / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D003692:Delayed-Action Preparations; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014202:Tremor / Q000188:drug therapy
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D010880:Piperidines; D014149:Tranquilizing Agents; D001712:Biperiden; D000433:1-Propanol
Essai clinique de l'Akinophyl-retard (Akinéton.